{"id":728,"date":"2020-02-01T08:59:10","date_gmt":"2020-02-01T07:59:10","guid":{"rendered":"http:\/\/invivo.partners\/?post_type=portoflio_invivo&#038;p=728"},"modified":"2021-09-02T12:24:13","modified_gmt":"2021-09-02T10:24:13","slug":"minoryx-therapeutics","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/","title":{"rendered":"Minoryx Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Minoryx Therapeutics es una empresa spin-off de la <strong>Universitat de Barcelona<\/strong> y el <strong>IDIBELL<\/strong>. La empresa se centra en el descubrimiento y desarrollo de nuevas terapias para enfermedades gen\u00e9ticas hu\u00e9rfanas y graves del sistema nervioso central (SNC). El candidato principal es un agonista PPAR gamma novedoso, selectivo y diferenciado (<strong>leriglitazona<\/strong>), que actualmente est\u00e1 en desarrollo cl\u00ednico en la adrenomieloneuropat\u00eda (<strong>AMN<\/strong>), en la adrenoleucodistrofia cerebral (<strong>cALD<\/strong>) y en la ataxia de Friedreich (<strong>FDRA<\/strong>).<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>CEO y cofundador: Marc Martinell<\/li><li>Ubicaci\u00f3n: Matar\u00f3 (Barcelona) y Gosselies (B\u00e9lgica)<\/li><li>P\u00e1gina web: <strong><a rel=\"noreferrer noopener\" href=\"http:\/\/www.minoryx.com\/\" target=\"_blank\">minoryx.com<\/a><\/strong><\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[506],"class_list":["post-728","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-healthequity"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Minoryx Therapeutics - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Minoryx Therapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Minoryx Therapeutics es una empresa spin-off de la Universitat de Barcelona y el IDIBELL. La empresa se centra en el descubrimiento y desarrollo de nuevas terapias para enfermedades gen\u00e9ticas hu\u00e9rfanas y graves del sistema nervioso central (SNC). El candidato principal es un agonista PPAR gamma novedoso, selectivo y diferenciado (leriglitazona), que actualmente est\u00e1 en desarrollo\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-02T10:24:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/\",\"url\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/\",\"name\":\"Minoryx Therapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-01T07:59:10+00:00\",\"dateModified\":\"2021-09-02T10:24:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Minoryx Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Minoryx Therapeutics - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"Minoryx Therapeutics - Invivo Partners","og_description":"Minoryx Therapeutics es una empresa spin-off de la Universitat de Barcelona y el IDIBELL. La empresa se centra en el descubrimiento y desarrollo de nuevas terapias para enfermedades gen\u00e9ticas hu\u00e9rfanas y graves del sistema nervioso central (SNC). El candidato principal es un agonista PPAR gamma novedoso, selectivo y diferenciado (leriglitazona), que actualmente est\u00e1 en desarrollo","og_url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/","og_site_name":"Invivo Partners","article_modified_time":"2021-09-02T10:24:13+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/","url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/","name":"Minoryx Therapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-01T07:59:10+00:00","dateModified":"2021-09-02T10:24:13+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/minoryx-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"Minoryx Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo\/728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=728"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tipo_portfolio?post=728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}